Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | EDNRB | P24530 | 1/20 | 0.35 |
| ▸ | EDNRA | P25101 | 1/20 | 0.35 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.35 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19330413 | 0.92 | ALDH1A1 (0.39) | SMN1; SMN2NPC1ALDH1A1MAPK1RAB9A | |
| SCHEMBL20776991 | 0.88 | SMN1; SMN2 (0.36) | SMN1; SMN2NPC1ALDH1A1MAPK1RAB9A | |
| SCHEMBL19330246 | 0.88 | SMN1; SMN2 (0.38) | SMN1; SMN2NPC1ALDH1A1MAPK1RAB9A | |
| SCHEMBL19330128 | 0.78 | SMN1; SMN2 (0.42) | SMN1; SMN2NPC1ALDH1A1MAPK1RAB9A | |
| SCHEMBL2940362 | 0.78 | RECQL (0.50) | NPC1RAB9AMAPTS1PR1S1PR3 | |
| SCHEMBL19330247 | 0.77 | ALDH1A1 (0.38) | ALDH1A1MAPTEDNRBEDNRATHRB | |
| SCHEMBL2547333 | 0.77 | ALDH1A1 (0.47) | SMN1; SMN2NPC1ALDH1A1RAB9AMAPT | |
| SCHEMBL4469982 | 0.75 | SMN1; SMN2 (0.46) | SMN1; SMN2NPC1ALDH1A1MAPK1RAB9A | |
| SCHEMBL3822083 | 0.75 | NQO1 (0.48) | SMN1; SMN2NPC1ALDH1A1MAPK1RAB9A | |
| SCHEMBL7464556 | 0.75 | ALDH1A1 (0.55) | SMN1; SMN2NPC1ALDH1A1MAPK1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109069514-B | Antibacterial compound and application thereof | 结核病药物开发全球联盟公司 | 2023-12-29 | — | — | CN | disclosed |
| EP-4148053-A1 | ANTIBACTERIAL COMPOUNDS AND USES THEREOF | The Global Alliance for TB Drug Development, Inc. (US) | 2023-03-15 | — | — | EP | disclosed |
| EP-3426255-B1 | ANTIBACTERIAL COMPOUNDS AND USES THEREOF | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC (US) | 2022-11-30 | — | — | EP | disclosed |
| EP-3426255-B1 | ANTIBACTERIAL COMPOUNDS AND USES THEREOF | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC (US) | 2022-11-30 | — | — | EP | disclosed |
| US-10981891-B2 | Antibacterial compounds and uses thereof | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) | 2021-04-20 | — | — | US | disclosed |
| US-10981891-B2 | Antibacterial compounds and uses thereof | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) | 2021-04-20 | — | — | US | disclosed |
| US-20200039955-A1 | ANTIBACTERIAL COMPOUNDS AND USES THEREOF | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. | 2020-02-06 | — | — | US | disclosed |
| US-20200039955-A1 | ANTIBACTERIAL COMPOUNDS AND USES THEREOF | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. | 2020-02-06 | — | — | US | disclosed |
| US-10508097-B2 | Antibacterial compounds and uses thereof | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) | 2019-12-17 | — | — | US | disclosed |
| US-10508097-B2 | Antibacterial compounds and uses thereof | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) | 2019-12-17 | — | — | US | disclosed |
| WO-2017155909-A1 | ANTIBACTERIAL COMPOUNDS AND USES THEREOF | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) | 2017-09-14 | — | — | WO | disclosed |
| WO-2017155909-A1 | ANTIBACTERIAL COMPOUNDS AND USES THEREOF | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) | 2017-09-14 | — | — | WO | disclosed |
| US-8178559-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-05-15 | — | — | US | disclosed |
| US-8084450-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-12-27 | — | — | US | disclosed |
| US-20110263560-A1 | Organic Compounds | NOVARTIS AG (CH) | 2011-10-27 | — | — | US | disclosed |
| EP-2177518-A1 | Organic compounds | Novartis AG (CH) | 2010-04-21 | — | — | EP | disclosed |
| US-20090312304-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-12-17 | — | — | US | disclosed |
| EP-1833816-B1 | SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2009-11-11 | — | — | EP | disclosed |
| EP-1833816-A1 | SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS | Novartis AG (CH) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006069788-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10981891-B2 | Antibacterial compounds and uses thereof | CFTR, SQOR, NQO1 | SMN1; SMN2 3620/4885NPC1 534/4885ALDH1A1 518/4885 |
| US-20200039955-A1 | ANTIBACTERIAL COMPOUNDS AND USES THEREOF | CFTR, SQOR, NQO1 | SMN1; SMN2 3620/4885NPC1 534/4885ALDH1A1 518/4885 |
| US-20110263560-A1 | Organic Compounds | REN, ACE, OTC | SMN1; SMN2 2243/4885NPC1 2742/4885ALDH1A1 21/4885 |
| US-10508097-B2 | Antibacterial compounds and uses thereof | CFTR, SQOR, NQO1 | SMN1; SMN2 3620/4885NPC1 534/4885ALDH1A1 518/4885 |
| US-20090312304-A1 | ORGANIC COMPOUNDS | REN, ACE, PIGO | SMN1; SMN2 2488/4885NPC1 1874/4885ALDH1A1 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.